{
  "docId": "019de076-0698-71a3-a9aa-98e37bdedc21",
  "docSlug": "bc2296074db02088be88a45da2f9e973",
  "documentTitle": "Mainz Biomed NV | Investor Presentation Deck | 27 slides",
  "authorId": "mainz-biomed-nv",
  "authorName": "Mainz Biomed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 27,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-0698-71a3-a9aa-98e37bdedc21/3",
  "deckHref": "/decks/019de076-0698-71a3-a9aa-98e37bdedc21",
  "deckJsonHref": "/decks/019de076-0698-71a3-a9aa-98e37bdedc21.json",
  "deckAnchorHref": "/decks/019de076-0698-71a3-a9aa-98e37bdedc21#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "list",
      "text": "Highly-differentiated flagship product (ColoAlert®): Highly efficacious, at-home, stool-based screening test for early colorectal cancer (CRC) detection; Combines a FIT test for detection of human hemoglobin with the PCR results of specific tumor DNA markers; Marketed as a CE-IVD product in Europe since 2021",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "085f3204-0a4c-45f0-9fd7-49a39dbb4e2e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.67,
        "y": 0.15
      },
      "kind": "list",
      "text": "Disruptive, decentralized business model: Kit-based solution that allows the testing to be done in any lab across the United States; All competitors using CLIA laboratory based centralized solutions that require large investments to broadly commercialize the product nationally; Enables the sale of ColoAlert® internationally",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "097ac534-0412-4c55-b43e-520155b7a609",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.67,
        "y": 0.55
      },
      "kind": "list",
      "text": "Strong intellectual property position: Valuable IP position, with new IP in development; Trade secret portfolio",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15019908-2d68-4322-9ac9-259050db3b42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.35,
        "y": 0.55
      },
      "kind": "list",
      "text": "Strong team: Experienced diagnostics team, formerly Roche, Abbott or Qiagen; took the company public in 2021; 64 employees with headquarters in Mainz, Germany; Strong Medical Advisory Board with renowned scientific and oncology experts",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16ddfbf3-29e7-4383-a244-527d6f2c9c6d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.03,
        "y": 0.55
      },
      "kind": "list",
      "text": "Disruptive next-gen product (in development): Expanding current test to add novel, proprietary mRNA biomarkers to increase the detection of advanced adenomas; Early detection of advanced adenomas (precancerous lesions) could drastically reduce or even eliminate cancer; Two ongoing clinical trials with data reported in 2023; planning to initiate recruitment for FDA PMA pivotal study in mid 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b0b9283-b412-400e-9a09-5a262a20f04e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.35,
        "y": 0.15
      },
      "kind": "list",
      "text": "Significant market opportunity: $10bn+ global CRC market (3rd most-commonly diagnosed cancer; 2nd leading cause of cancer death globally); Ability to move into large, adjacent areas, including pancreatic cancer and other GI cancers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5677c60-8753-4958-bdea-166bbfdea572",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Mainz Biomed Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d117847-5a5e-425d-abe5-edbab7a1624e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}